贝伐单抗联合伊立替康对接种人结肠癌SW480细胞裸鼠的肝脏损伤研究

Effects of Bevacizumab and Irinotecan on Hepatic Injury of Nude Mice Transplanted with Human Colocarcinoma SW480 Cell

目的研究贝伐单抗是否可以影响伊立替康所致肝脏脂肪变性的发生率和严重程度。方法建立结肠癌SW480细胞裸鼠皮下移植瘤模型,皮下注射伊立替康或伊立替康联合贝伐单抗,制作肝脏病理切片并观察肝脏的损伤情况,Realtime PCR检测肿瘤及肝脏组织内VEGF mRNA的表达情况。结果成功建立了结肠癌SW480细胞裸鼠皮下移植瘤模型;联合贝伐单抗组裸鼠肝脏脂肪变性的发生率降低,且肝脏内和肿瘤组织内VEGF mRNA的表达水平均显著低于单用伊立替康组(P<0.05)。结论贝伐单抗可降低伊立替康引起的肝脏脂肪变性的发生率。

Objective To investigate whether bevacizumab make impact on the incidence rate and severe degree of hepatic steatosis caused by irinotecan.Methods Nude mice sub-skin model was constructed by transplanting human colocarcinoma SW480 cells,then injected irinotecan with(observation group)or without bevacizumab(control group).The hepatic injury was observed by pathological section and HE staining.The expression of VEGF mRNA in hepatic or tumor tissues was observed by real-time PCR.Results The subcutaneous tumor model with human colocarcinoma SW480 cells in nude mice was successfully constructed.The incidence rate of hepatic steatosis was lower in observation group than in control group(P<0.05).The expre ssion of VEGF mRNA in hepatic or tumor tissues was lower in observation group than in control group(P<0.05).Conclusion Bevacizumab can reduce the incidence rate of hepatic steatosis caused by irinotecan.